203 related articles for article (PubMed ID: 26302712)
1. Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo.
Jorfi S; Ansa-Addo EA; Kholia S; Stratton D; Valley S; Lange S; Inal J
Sci Rep; 2015 Aug; 5():13006. PubMed ID: 26302712
[TBL] [Abstract][Full Text] [Related]
2. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
Gravina GL; Marampon F; Petini F; Biordi L; Sherris D; Jannini EA; Tombolini V; Festuccia C
Endocr Relat Cancer; 2011 Aug; 18(4):385-400. PubMed ID: 21551258
[TBL] [Abstract][Full Text] [Related]
3. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
[TBL] [Abstract][Full Text] [Related]
4. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
[TBL] [Abstract][Full Text] [Related]
5. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer.
Qu MH; Zeng RF; Fang S; Dai QS; Li HP; Long JT
Int J Pharm; 2014 Oct; 474(1-2):112-22. PubMed ID: 25138252
[TBL] [Abstract][Full Text] [Related]
6. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
[TBL] [Abstract][Full Text] [Related]
7. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
8. Effective photothermal chemotherapy with docetaxel-loaded gold nanospheres in advanced prostate cancer.
Shen Y; Ma Z; Chen F; Dong Q; Hu Q; Bai L; Chen J
J Drug Target; 2015; 23(6):568-76. PubMed ID: 25738990
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model.
Mirjolet C; Boudon J; Loiseau A; Chevrier S; Boidot R; Oudot A; Collin B; Martin E; Joy PA; Millot N; Créhange G
Int J Nanomedicine; 2017; 12():6357-6364. PubMed ID: 28919739
[TBL] [Abstract][Full Text] [Related]
10. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
[TBL] [Abstract][Full Text] [Related]
12. [Effect of sodium phenylbutyrate on the sensitivity of PC3/DTX-resistant prostate cancer cells to docetaxel].
Xu YW; Zheng SB; Chen BS; Wen Y; Zhu SW
Nan Fang Yi Ke Da Xue Xue Bao; 2017 Novemer 20; 37(1):130-134. PubMed ID: 28109113
[TBL] [Abstract][Full Text] [Related]
13. Low-dose Docetaxel Enhanced the Anticancer Effect of Temsirolimus by Overcoming Autophagy in Prostate Cancer Cells.
Inamura SO; Ito H; Taga M; Tsuchiyama K; Hoshino H; Kobayashi M; Yokoyama O
Anticancer Res; 2019 Oct; 39(10):5417-5425. PubMed ID: 31570436
[TBL] [Abstract][Full Text] [Related]
14. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
Yan J; Wang Y; Zhang X; Liu S; Tian C; Wang H
Drug Deliv; 2016 Jun; 23(5):1757-62. PubMed ID: 26203689
[TBL] [Abstract][Full Text] [Related]
15. In vivo evidence of gamma-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer.
Yap WN; Zaiden N; Luk SY; Lee DT; Ling MT; Wong YC; Yap YL
Pharmacology; 2010; 85(4):248-58. PubMed ID: 20375535
[TBL] [Abstract][Full Text] [Related]
16. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two kinds of docetaxel-vitamin E prodrugs: In vitro evaluation and in vivo antitumor activity.
Wang J; Xue P; Zhou J; Li L; Xu L; Wang Y
Int J Pharm; 2016 May; 505(1-2):352-60. PubMed ID: 27085643
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.
Huang SF; Kim SJ; Lee AT; Karashima T; Bucana C; Kedar D; Sweeney P; Mian B; Fan D; Shepherd D; Fidler IJ; Dinney CP; Killion JJ
Cancer Res; 2002 Oct; 62(20):5720-6. PubMed ID: 12384530
[TBL] [Abstract][Full Text] [Related]
19. In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role?
Ostacolo L; Marra M; Ungaro F; Zappavigna S; Maglio G; Quaglia F; Abbruzzese A; Caraglia M
J Control Release; 2010 Dec; 148(2):255-63. PubMed ID: 20816710
[TBL] [Abstract][Full Text] [Related]
20. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.
Liu D; Liu Z; Wang L; Zhang C; Zhang N
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):262-9. PubMed ID: 21435845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
